4th Quarter - Termination Amendment

SANOFI PASTEUR, INC. (FORMERLY AVENTIS PASTEUR) for SANOFI PASTEUR INC (FORMERLY AVENTIS PASTEUR)

Period 4th Quarter 2010 Filed Mar 16, 2011 Signed by Ronald M. Jacobs, Counsel

Official filing
Firm
SANOFI PASTEUR, INC. (FORMERLY AVENTIS PASTEUR)
Client
SANOFI PASTEUR INC (FORMERLY AVENTIS PASTEUR)
Income
—
Expenses
$623,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Dec 31, 2010

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 20, 2011 $623,000 Replaced
4th Quarter - Termination Amendment (this page) Mar 16, 2011 $623,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Vaccine-related legislation, advance market commitments, and other issues

Foreign entity interest: Sanofi-Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
MARYANNE DOLBEARE DUNLAP —
AMY L REDL —

Contacted: Homeland Security, Dept of (DHS); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

Patent reform issues

Foreign entity interest: Sanofi-Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
MARYANNE DOLBEARE DUNLAP —
AMY L REDL —

Contacted: Homeland Security, Dept of (DHS); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Legislation and other issues involving vaccine taxes and children's health, vaccine-related issues with respect to Medicaid and Medicare, and vaccine-related general tax issues.

Foreign entity interest: Sanofi-Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
MARYANNE DOLBEARE DUNLAP —
AMY L REDL —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Homeland Security, Dept of (DHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Health Issues HCR

Vaccine and generic biological issues and related appropriation issues, including vaccines for children, pandemic concerns, influenza vaccine issues, stockpile, bioterrorism, bioterrorism countermeasures, vaccine injury compensation programs, vaccine safety, and FDA and CDC funding; implementation of health care reform legislation as it pertains to vaccines.

Foreign entity interest: Sanofi-Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
MARYANNE DOLBEARE DUNLAP —
AMY L REDL —

Contacted: SENATE; Homeland Security, Dept of (DHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Vaccine-related Medicare and Medicaid issues, including those arising from implementation of health care reform legislation.

Foreign entity interest: Sanofi-Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
MARYANNE DOLBEARE DUNLAP —
AMY L REDL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Homeland Security, Dept of (DHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.